James E. Hoffman
Expertise in
23
conditions

Dr. James E. Hoffman

Hematology Oncology
1192 East Newport Center Drive, 
Deerfield Beach, FL 
Accepting New Patients
Offers Telehealth
Expertise in
23
conditions
1192 East Newport Center Drive, 
Deerfield Beach, FL 

Overview

James Hoffman is a Hematologist Oncology provider practicing medicine in Deerfield Beach, Florida.

Dr. Hoffman is highly rated in 23 conditions, according to our data. His clinical expertise encompasses Multiple Myeloma, Primary Amyloidosis, Cardiac Amyloidosis, and Smoldering Multiple Myeloma.

He is actively involved in clinical research, co-authoring 55 peer reviewed articles and participating in 8 clinical trials. Dr. Hoffman is currently accepting new patients.

Specialties

Hematology Oncology

Licenses

Internal Medicine in FL

Fellowships

Memorial Sloan-Kettering Cancer Center, Hematology/Oncology - 2009

Hospital Affiliations

Cleveland Clinic Hospital

Languages Spoken

English
Hebrew

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
AvMed
  • HMO
  • POS
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Florida Blue
  • EPO
  • PPO
Freedom Health
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
Guardian Life Insurance Company
  • MEDICARE PDP
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Health First
  • HMO
  • POS
Health Options
  • HMO
  • POS
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Icare Independent Care Health Plan
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE SNP
Independent Health
  • EPO
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
MetLife
  • PPO
Neighborhood
  • MANAGED MEDICAID PLAN
  • MEDICARE ASSISTANCE PROGRAM
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
Oscar
  • EPO
  • HMO
  • PPO
Simply Healthcare
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER MEDICARE PART D
Sunshine Health
  • EPO
  • HMO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 19 Less Insurance Carriers -

Locations

1192 East Newport Center Drive, Deerfield Beach, FL 33442
Other Locations
1475 Northwest 12th Avenue, Miami, FL 33136

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

Randomized Phase III Trial of Bortezomib, Lenalidomide, and Dexamethasone (VRd) Versus Carfilzomib, Lenalidomide, and Dexamethasone (CRd) Followed by Limited or Indefinite Duration Lenalidomide Maintenance in Patients With Newly Diagnosed Symptomatic Multiple Myeloma (ENDURANCE)
Randomized Phase III Trial of Bortezomib, Lenalidomide, and Dexamethasone (VRd) Versus Carfilzomib, Lenalidomide, and Dexamethasone (CRd) Followed by Limited or Indefinite Duration Lenalidomide Maintenance in Patients With Newly Diagnosed Symptomatic Multiple Myeloma (ENDURANCE)
Enrollment Status: Active_not_recruiting
Publish Date: September 08, 2025
Intervention Type: Other, Drug
Study Drugs: Bortezomib, Carfilzomib, Dexamethasone, Lenalidomide
Study Phase: Phase 3
A Phase 1 Study of SEA-BCMA in Patients With Relapsed or Refractory Multiple Myeloma
A Phase 1 Study of SEA-BCMA in Patients With Relapsed or Refractory Multiple Myeloma
Enrollment Status: Terminated
Publish Date: December 24, 2024
Intervention Type: Drug
Study Drugs: SEA-BCMA, Dexamethasone, Pomalidomide
Study Phase: Phase 1
Screening to Improve Survival in AL Amyloidosis
Screening to Improve Survival in AL Amyloidosis
Enrollment Status: Completed
Publish Date: October 28, 2024
A Phase 1a/1b Multicenter, Single-Arm, Open-Label, Dose-Escalation Study to Determine the Maximum Tolerated Dose, Safety, and Preliminary Activity of Oral ACY-241 Alone and in Combination With Pomalidomide and Low-Dose Dexamethasone in Patients With Relapsed or Relapsed-and-Refractory Multiple Myeloma
A Phase 1a/1b Multicenter, Single-Arm, Open-Label, Dose-Escalation Study to Determine the Maximum Tolerated Dose, Safety, and Preliminary Activity of Oral ACY-241 Alone and in Combination With Pomalidomide and Low-Dose Dexamethasone in Patients With Relapsed or Relapsed-and-Refractory Multiple Myeloma
Enrollment Status: Terminated
Publish Date: July 09, 2024
Intervention Type: Drug
Study Drugs: ACY-241, Pomalidomide, Dexamethasone
Study Phase: Phase 1
A Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled, 2-Arm, Efficacy and Safety Study of NEOD001 Plus Standard of Care Versus Placebo Plus Standard of Care in Subjects With Light Chain (AL) Amyloidosis
A Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled, 2-Arm, Efficacy and Safety Study of NEOD001 Plus Standard of Care Versus Placebo Plus Standard of Care in Subjects With Light Chain (AL) Amyloidosis
Enrollment Status: Terminated
Publish Date: November 14, 2023
Intervention Type: Other, Drug
Study Phase: Phase 3
A Phase 2b, Open-Label, Single-Arm Study of Selinexor (KPT-330) Plus Low-Dose Dexamethasone (Sd) in Patients With Multiple Myeloma Previously Treated With Lenalidomide, Pomalidomide, Bortezomib, Carfilzomib, and an Anti-CD38 Monoclonal Antibody (mAb) Daratumumab, and Refractory to Prior Treatment With Glucocorticoids, an Immunomodulatory Agent, a Proteasome Inhibitor, and an the Anti-CD38 mAb Daratumumab
A Phase 2b, Open-Label, Single-Arm Study of Selinexor (KPT-330) Plus Low-Dose Dexamethasone (Sd) in Patients With Multiple Myeloma Previously Treated With Lenalidomide, Pomalidomide, Bortezomib, Carfilzomib, and an Anti-CD38 Monoclonal Antibody (mAb) Daratumumab, and Refractory to Prior Treatment With Glucocorticoids, an Immunomodulatory Agent, a Proteasome Inhibitor, and an the Anti-CD38 mAb Daratumumab
Enrollment Status: Completed
Publish Date: January 26, 2023
Intervention Type: Drug
Study Phase: Phase 2
Open-Label Pilot Study to Assess the Safety, Tolerability and Antitumor Activity of Genetically Engineered NY-ESO-1 Specific (c259) T Cells Alone or in Combination With Pembrolizumab in HLA-A2+ Subjects With NY-ESO-1 and/or LAGE-1a Positive Relapsed and Refractory Multiple Myeloma
Open-Label Pilot Study to Assess the Safety, Tolerability and Antitumor Activity of Genetically Engineered NY-ESO-1 Specific (c259) T Cells Alone or in Combination With Pembrolizumab in HLA-A2+ Subjects With NY-ESO-1 and/or LAGE-1a Positive Relapsed and Refractory Multiple Myeloma
Enrollment Status: Terminated
Publish Date: January 11, 2022
Intervention Type: Drug
Study Drugs: Letetresgene Autoleucel, Letetresgene Autoleucel with Pembrolizumab, Fludarabine, Cyclophosphamide, Pembrolizumab
Study Phase: Phase 1
Collection of Peripheral Blood Samples From Patients With Carpal Tunnel Syndrome for Laboratory Screening of Amyloidosis
Collection of Peripheral Blood Samples From Patients With Carpal Tunnel Syndrome for Laboratory Screening of Amyloidosis
Enrollment Status: Completed
Publish Date: August 26, 2021
View 7 Less Clinical Trials

55 Total Publications

Linvoseltamab versus elranatamab for triple-class exposed relapsed or refractory multiple myeloma: an indirect treatment comparison.
Linvoseltamab versus elranatamab for triple-class exposed relapsed or refractory multiple myeloma: an indirect treatment comparison.
Journal: Leukemia & lymphoma
Published: July 10, 2026
Similar Doctors
Expertise in
21
conditions
Dr. Izidore S. Lossos
Hematology Oncology | Hematology
Expertise in
21
conditions
Dr. Izidore S. Lossos
Hematology Oncology | Hematology
Referral may be required
1475 Northwest 12th Avenue, 
Miami, FL 
 (35.9 miles away)
305-243-5302
Languages Spoken:
English, Hebrew, Russian, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Izidore Lossos is a Hematologist Oncology specialist and a Hematologist practicing medicine in Miami, Florida. Dr. Lossos is highly rated in 21 conditions, according to our data. His clinical expertise encompasses Non-Hodgkin Lymphoma, Marginal Zone Lymphoma (MZL), B-Cell Lymphoma, Follicular Lymphoma, and Bone Marrow Transplant. Dr. Lossos is currently accepting new patients.

Expertise in
23
conditions
Dr. Mikkael A. Sekeres
Hematology Oncology | Hematology
Expertise in
23
conditions
Dr. Mikkael A. Sekeres
Hematology Oncology | Hematology
Referral may be required
1425 Northwest 10th Avenue, 
Miami, FL 
 (35.9 miles away)
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

His research focuses on patients with myelodysplastic syndromes (MDS) and older adults with acute myeloid leukemia (AML). Dr. Sekeres is highly rated in 23 conditions, according to our data. His clinical expertise encompasses Myelodysplastic Syndrome (MDS), Acute Myeloid Leukemia (AML), Leukemia, Bone Marrow Aspiration, and Bone Marrow Transplant. Dr. Sekeres is currently accepting new patients.

Expertise in
26
conditions
Dr. Rafat Abonour
Hematology Oncology
Expertise in
26
conditions
Dr. Rafat Abonour
Hematology Oncology
Referral may be required
2111 Sole Mia Way 5th, 
Miami, FL 
 (27.9 miles away)
305-243-5302
Languages Spoken:
English, Arabic, French
See accepted insurances
Accepting New Patients
Offers Telehealth

Rafat Abonour is a Hematologist Oncology provider practicing medicine in Miami, Florida. Dr. Abonour is highly rated in 26 conditions, according to our data. His clinical expertise encompasses Multiple Myeloma, Smoldering Multiple Myeloma, Primary Amyloidosis, Relapsed Refractory Multiple Myeloma (RRMM), and Bone Marrow Transplant. Dr. Abonour is currently accepting new patients.

Frequently Asked Questions about Dr. James E. Hoffman

How do I make an appointment with Dr. James E. Hoffman?

You can book an appointment with Dr. James E. Hoffman by calling their office at 305-243-5302. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. James E. Hoffman a top-rated expert for Multiple Myeloma?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. James E. Hoffman is classified as an Elite expert for Multiple Myeloma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. James E. Hoffman specialize in?

While Dr. James E. Hoffman is a Hematology Oncology, they have specific expertise in Multiple Myeloma, Primary Amyloidosis, and Cardiac Amyloidosis. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology Oncology.

Does Dr. James E. Hoffman participate in research or clinical trials?

Yes. Dr. James E. Hoffman has published 55 articles and abstracts on conditions like Multiple Myeloma. You can view a list of Dr. James E. Hoffman's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. James E. Hoffman accept my insurance?

Dr. James E. Hoffman accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 305-243-5302 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Hoffman's expertise for a condition
ConditionClose
View All 12 Distinguished Conditions
View All 9 Advanced Conditions
View All 43 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile